ClinicalTrials.gg
CompletedNCT00002159Updated Jun 24, 2005

A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis

A Phase 3 interventional study of Itraconazole and Amphotericin B in HIV Infections, Histoplasmosis and Blastomycosis, sponsored by Janssen, LP. Completed at 9 sites in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Janssen, LP (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing Amphotericin B in HIV Infections — none open to participants now, none under way, none of them phase 3. Amphotericin B · HIV Infections.

Phase 3
5 of 16
none open now
Registered
1st of 16
by date
Lead sponsor
1 of 16
Janssen, LP

Among the 16 studies testing Amphotericin B in HIV Infections, this one is one of 5 in phase 3, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 16 studies testing Amphotericin B in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About Amphotericin B

Amphotericin B: first FDA approval 1964 (FUNGIZONE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing Amphotericin B in HIV Infections as a file.
02

Study summary

To assess the safety of intravenous itraconazole compared to amphotericin B in HIV positive or negative persons with blastomycosis or histoplasmosis.

Read the detailed description

Patients are randomized to receive IV itraconazole for 2 days, then either itraconazole daily for 5 days or amphotericin B daily for 7 days. IV treatment is followed by consolidation with oral itraconazole for up to 1 year.

03

Conditions studied

  • HIV Infections
  • Histoplasmosis
  • Blastomycosis

Keywords

  • Itraconazole
  • Histoplasmosis
  • Antifungal Agents
  • Acquired Immunodeficiency Syndrome
  • Amphotericin B
  • AIDS-Related Complex
  • Blastomycosis
  • Antibiotics, Antifungal
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • positive or negative status.
  • Blastomycosis or histoplasmosis.
  • of at least 1 week.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Liver disease.
  • Self-limiting fungal disease.
  • Very severe fungal disease such as meningeal involvement.
  • Acute respiratory disease.

Concurrent Medication:

Excluded at any time:

  • Terfenadine.
  • Astemizole.
  • Oral midazolam.
  • Triazolam.
  • Cisapride.
  • Phenytoin.
  • Phenobarbital.
  • Rifampin.
  • Rifabutin.

Excluded during oral consolidation:

  • H2 blockers.
  • Chronic antacids.
  • Omeprazole.
  • Lansoprazole.

Patients with the following prior condition are excluded:

to azole antifungals.

Prior Medication:

Excluded at any time:

More than 3 days of amphotericin B, fluconazole, or ketoconazole.

Excluded within 2 weeks prior to study entry:

  • Phenytoin.
  • Phenobarbital.
  • Rifampin.
  • Rifabutin.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Enrollment
60 participants

Interventions

06

Study locations

9 sites
  • UAB Station / Infectious Division
    Birmingham, Alabama 35294, United States
  • Univ of Arkansas for Med Sciences
    Little Rock, Arkansas 72205, United States
  • Division of Infectious Diseases
    Atlanta, Georgia 30303, United States
  • Division of Inf Diseases/ Indiana Univ Hosp
    Indianapolis, Indiana 46202, United States
  • Community Hosp
    Indianapolis, Indiana 46218, United States
  • LSU Med Ctr / Div of Pulmonary & Critical Care Med
    Shreveport, Louisiana 71130, United States
  • Ann Arbor Veterans Administration Med Ctr
    Ann Arbor, Michigan 48105, United States
  • Univ of Missouri / Division of Infectious Diseases
    Kansas City, Missouri 641082792, United States
  • Infectious Diseases Association / Research Med Ctr
    Kansas City, Missouri 64132, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002159
Lead sponsor
Janssen, LP
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 1997. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Itraconazole · Amphotericin B

Start the discussion